These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31721701)

  • 1. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.
    Muñoz M; Rosso M; Coveñas R
    Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    Coveñas R; Rodríguez FD; Robinson P; Muñoz M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
    Robinson P; Coveñas R; Muñoz M
    Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
    Muñoz M; Coveñas R
    Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
    Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach.
    Muñoz M; Coveñas R
    Anticancer Agents Med Chem; 2019; 19(1):92-100. PubMed ID: 29692265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
    Munoz M; Covenas R; Esteban F; Redondo M
    J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
    Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
    Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
    Muñoz M; Rosso M; Coveñas R
    Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
    Shi Y; Wang X; Meng Y; Ma J; Zhang Q; Shao G; Wang L; Cheng X; Hong X; Wang Y; Yan Z; Cao Y; Kang J; Fu C
    Adv Sci (Weinh); 2021 Nov; 8(21):e2101936. PubMed ID: 34605226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the research and application of neurokinin-1 receptor antagonists.
    Hong X; Ma J; Zheng S; Zhao G; Fu C
    J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.
    Martín-García D; Téllez T; Redondo M; García-Aranda M
    Curr Med Chem; 2024; 31(39):6487-6509. PubMed ID: 37861026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
    Muñoz M; Rosso M; Coveñas R
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of neurokinin-1 receptor antagonists.
    Muñoz M; Coveñas R
    Expert Opin Drug Saf; 2013 Sep; 12(5):673-85. PubMed ID: 23706125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
    Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
    Muñoz M; Coveñas R
    World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NK-1 receptor: a new target in cancer therapy.
    Muñoz M; Rosso M; Coveñas R
    Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer progression and substance P.
    Coveñas R; Muñoz M
    Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
    Muñoz M; Coveñas R
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.